This bill establishes new requirements for health plans in Washington State regarding coverage for biomarker testing, effective January 1, 2026. It mandates that health carriers, public employee health plans, and the authority administering medical assistance programs must provide coverage for biomarker testing when it is supported by medical and scientific evidence. The criteria for coverage include tests approved by the FDA, national coverage determinations from Medicare, and guidelines from recognized clinical practice organizations. The bill emphasizes the importance of minimizing disruptions in patient care, such as the need for multiple biopsies or biospecimen samples.

Additionally, the bill defines key terms related to biomarker testing, including "biomarker," which refers to measurable characteristics indicating biological processes or responses to treatment, and "biomarker testing," which involves analyzing patient samples for these indicators. The definitions also encompass "consensus statements" and "nationally recognized clinical practice guidelines," ensuring that the coverage criteria are based on established medical standards and evidence. Overall, the legislation aims to enhance patient care by ensuring access to necessary diagnostic and treatment tools through biomarker testing.